Fedor V Moiseyenko

8PUBLICATIONS
43CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 28, 2025
Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer.

Fedor Moiseenko, Andrey Kechin, Maksim Koryukov

|Jun 13, 2025
Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations.

Fedor Moiseenko, Marko Radulovic, Nadezhda Tsvetkova

|Sep 04, 2024
Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors.

Fedor Moiseenko, Ekaterina Kuligina, Ekaterina Elsakova

|Jun 06, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

D Ross Camidge, Jair Bar, Hidehito Horinouchi

|Feb 11, 2023
Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in <i>BRCA1</i>-Driven Breast Cancer Patients.

Anna P Sokolenko, Fedor V Moiseyenko, Aglaya G Iyevleva

|Oct 21, 2022
Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.

Fedor Moiseenko, Alexey Bogdanov, Vitaliy Egorenkov

Pageof 2

Frequent Collaborators

3 joint publications

Evgeny N Imyanitov

3 joint publications

Ekaterina S Kuligina

2 joint publications

Albina S Zhabina

2 joint publications

Nikita Volkov